Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing

Journal of Experimental Medicine

Volumn 186, Issue 12, 1997, Pages 2045-2050

  Suda, Takashi ^a   Hashimoto, Hideo ^a,b   Tanaka, Masato ^b   Ochi, Takahiro ^b   Nagata, Shigekazu ^a,b  

^a OSAKA BIOSCIENCE INSTITUTE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CELL KILLING; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LIGANDS; MEMBRANE GLYCOPROTEINS; SOLUBILITY; T-LYMPHOCYTES;

EID: 0031452949     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.12.2045     Document Type: Article

References (30)

1. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:39-13.
2. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630-632.
3. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
4. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
5. Kondo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:409-413.
6. Via, C.S., P. Nguyen, A. Shustov, J. Drappa, and K.B. Elkon. 1996. A major role for the Fas pathway in acute graft-versus-host disease. J. Immunol. 157:5387-5393.
7. Braun, M.Y., B. Lowin, L. French, O.H. Acha, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657-661.
8. Giordano, C., G. Stassi, M.R. De, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi, and A. Galluzzo. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275:960-963.
9. + lymphocyte depletion and human immunodeficiency virus replication. Blood. 89:1357-1363.
10. Silvestris, F., P. Cafforio, M.A. Frassanito, M. Tucci, A. Romito, S. Nagata, and F. Dammacco. 1996. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. AIDS. 10: 131-141.
11. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
12. Black, R.A., C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 385: 729-733.
13. Moss, M.L., S.L. Jin, M.E. Milla, W. Burkhart, H.L. Carter, W.J. Chen, W.C. Clay, J.R. Didsbury, D. Hassler, C.R. Hoffman et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 385:733-736.
14. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 14:1129-1135.
15. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-1783.
16. Suda, T., M. Tanaka, K. Miwa, and S. Nagata. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 157:3918-3924.
17. Wong, G.H.W., and D.V. Goeddel. 1994. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol. 152:1751-1755.
18. Shima, Y., N. Nishimoto, A. Ogata, Y. Fujii, K. Yoshizaki, and T. Kishimoto. 1995. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 85:757-764.
19. Owen-Schaub, L.B., S. Yonehara, W.L. Crump III, and E.A. Grimm. 1992. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol. 140:197-205.
20. Miyawaki, T., T. Uehara, R. Nibu, T. Tsuji, A. Yachie, S. Yonehara, and N. Taniguchi. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:3753-3758.
21. Robertson, M.J., T.J. Manley, G. Pichert, C. Cameron, K.J. Cochran, H. Levine, and J. Ritz. 1995. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk. Lymphoma 17:51-61.
22. Nishimura, Y., A. Ishii, Y. Kobayashi, Y. Yamasaki, and S. Yonehara. 1995. Expression and function of mouse Fas antigen on immature and mature T cells. J. Immunol. 154:4395-4403.
23. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga et al. 1996. Fas ligand in human serum. Nat. Med. 2:317-322.
24. Tanaka, M., T. Suda, T. Yatomi, N. Nakamura, and S. Nagata. 1997. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158: 2303-2309.
25. Ando, K., T. Moriyama, L.G. Guidotti, S. Wirth, R.D. Schreiber, H.J. Schlicht, S. Huang, and F.V. Chisari. 1993. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178: 1541-1554.
26. Grell, M., E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83:793-802.
27. Fadeel, B., C.J. Thorpe, S. Yonehara, and F. Chiodi. 1997. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int. Immunol. 9:201-209.
28. Trauth, B.C., C. Klas, A.M.J. Peters, S. Matzuku, P. Möller, W. Falk, K.-M. Debatin, and P.H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:301-305.
29. Owen-Schaub, L.B., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive ot biological responsiveness. Cancer Res. 54:1580-1586.
30. Fujisawa, K., H. Asahara, K. Okamoto, H. Aono, T. Hasunuma, T. Kobata, Y. Iwakura, S. Yonehara, T. Sumida, and K. Nishioka. 1996. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J. Clin. Invest. 98:271-278.